All In MedTech

Device Trial Radar · NCT04124588

Effectiveness of 'Nexpowder' for Hemostatic Treatments of Nonvariceal, Upper Gastrointestinal Bleeding

A Prospective, Multicenter, Randomized Controlled Trial to Evaluate Safety and Effectiveness of Endoscopic Hemostactic Powder, 'Nexpowder' for Hemostatic Treatments of Nonvariceal, Upper Gastrointestinal Bleeding

Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

348

Actual

Start

Nov 1, 2018

Primary completion

Oct 12, 2021

Study completion Nov 11, 2021

Sponsor

Lead sponsor
Next Biomedical Co., Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Oct 11, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, multi-center, randomized controlled trial to evaluate safety and effectiveness of endoscopic hemostatic powder, 'Nexpowder' for hemostatic treatments of nonvariceal upper gastrointestinal bleeding. This study is a prospective, multi-center, single blind (for patients), controlled investigation planned to evaluate safety and effectiveness of Nexpowder with 352 subject patients.

Conditions

  • Nonvariceal Upper Gastrointestinal Bleeding

Interventions

  • Nexpowder (Hemostatic powder)Device

    Nexpowder generates gelation-effects when the powder comes into contact with water, forms a physical barrier to control hemorrhage, preserve ulcer sites and thereby demonstrates its effective hemostatic performance. Hydrogels, which turned into gel-formation through water contacts in the gastrointestinal tract protect the wound sites for over 24 hours, are subsequently detached from the lesion, and completely excreted from the patient body system within 3 days.

  • Conventional TechniqueDevice

    Argon Plasma Coagulation, Coagulation including Forcep, Hemoclipping, Band Ligation, Epinephrine or Absolute Alcohol Injecction can be used as standard-of-care hemostatic treatment(s).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rates of re-bleedingTime frame: 3 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Soon Chun Hyang University Bucheon Hospital

    Gyeonggi-do, South Korea

  • Gachon Gil Hospital

    Incheon, South Korea

  • Inha University Hospital

    Incheon, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.